Personalised reimbursement: A risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

S. B. Van Waalwijk Van Doorn-Khosrovani; A. Pisters-Van Roy; L. Van Saase; M. Van Der Graaff; J. Gijzen; S. Sleijfer; L. R. Hoes; J. M. Van Berge Henegouwen; H. Van Der Wijngaart; D. L. Van Der Velden; E. Van Werkhoven; V. P. Retel; W. H. Van Harten; A. D.R. Huitema; L. Timmers; H. Gelderblom; H. M.W. Verheul; E. E. Voest

doi:10.1093/annonc/mdz119

Personalised reimbursement: A risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

S. B. Van Waalwijk Van Doorn-Khosrovani
, A. Pisters-Van Roy
, L. Van Saase
, M. Van Der Graaff
, J. Gijzen
, S. Sleijfer
, L. R. Hoes
, J. M. Van Berge Henegouwen
, H. Van Der Wijngaart
, D. L. Van Der Velden
, E. Van Werkhoven
, V. P. Retel
, W. H. Van Harten
, A. D.R. Huitema
, L. Timmers
, H. Gelderblom
, H. M.W. Verheul
, E. E. Voest

Research output: Contribution to journal › Editorial

34 Citations (Scopus)

Original language	English
Article number	mdz119
Pages (from-to)	663-665
Number of pages	3
Journal	Annals of Oncology
Volume	30
Issue number	5
DOIs	https://doi.org/10.1093/annonc/mdz119
Publication status	Published - May 2019
Externally published	Yes

Access to Document

10.1093/annonc/mdz119

Cite this

Van Waalwijk Van Doorn-Khosrovani, S. B., Pisters-Van Roy, A., Van Saase, L., Van Der Graaff, M., Gijzen, J., Sleijfer, S., Hoes, L. R., Van Berge Henegouwen, J. M., Van Der Wijngaart, H., Van Der Velden, D. L., Van Werkhoven, E., Retel, V. P., Van Harten, W. H., Huitema, A. D. R., Timmers, L., Gelderblom, H., Verheul, H. M. W., & Voest, E. E. (2019). Personalised reimbursement: A risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Annals of Oncology, 30(5), 663-665. Article mdz119. https://doi.org/10.1093/annonc/mdz119

@article{444dff5263bf48a69d5241a34e147f16,

title = "Personalised reimbursement: A risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients",

author = "\{Van Waalwijk Van Doorn-Khosrovani\}, \{S. B.\} and \{Pisters-Van Roy\}, A. and \{Van Saase\}, L. and \{Van Der Graaff\}, M. and J. Gijzen and S. Sleijfer and Hoes, \{L. R.\} and \{Van Berge Henegouwen\}, \{J. M.\} and \{Van Der Wijngaart\}, H. and \{Van Der Velden\}, \{D. L.\} and \{Van Werkhoven\}, E. and Retel, \{V. P.\} and \{Van Harten\}, \{W. H.\} and Huitema, \{A. D.R.\} and L. Timmers and H. Gelderblom and Verheul, \{H. M.W.\} and Voest, \{E. E.\}",

note = "Funding Information: The DRUP trial is supported by the Barcode for Life Foundation (grant number not applicable); the Dutch Cancer Society (grant number 10014); and all participating pharmaceutical companies (grant numbers not applicable): Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Novartis, Merck Sharp \& Dohme, Pfizer and Roche.",

year = "2019",

month = may,

doi = "10.1093/annonc/mdz119",

language = "English",

volume = "30",

pages = "663--665",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "5",

}

Van Waalwijk Van Doorn-Khosrovani, SB, Pisters-Van Roy, A, Van Saase, L, Van Der Graaff, M, Gijzen, J, Sleijfer, S, Hoes, LR, Van Berge Henegouwen, JM, Van Der Wijngaart, H, Van Der Velden, DL, Van Werkhoven, E, Retel, VP, Van Harten, WH, Huitema, ADR, Timmers, L, Gelderblom, H, Verheul, HMW & Voest, EE 2019, 'Personalised reimbursement: A risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients', Annals of Oncology, vol. 30, no. 5, mdz119, pp. 663-665. https://doi.org/10.1093/annonc/mdz119

TY - JOUR

T1 - Personalised reimbursement

T2 - A risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients

AU - Van Waalwijk Van Doorn-Khosrovani, S. B.

AU - Pisters-Van Roy, A.

AU - Van Saase, L.

AU - Van Der Graaff, M.

AU - Gijzen, J.

AU - Sleijfer, S.

AU - Hoes, L. R.

AU - Van Berge Henegouwen, J. M.

AU - Van Der Wijngaart, H.

AU - Van Der Velden, D. L.

AU - Van Werkhoven, E.

AU - Retel, V. P.

AU - Van Harten, W. H.

AU - Huitema, A. D.R.

AU - Timmers, L.

AU - Gelderblom, H.

AU - Verheul, H. M.W.

AU - Voest, E. E.

N1 - Funding Information: The DRUP trial is supported by the Barcode for Life Foundation (grant number not applicable); the Dutch Cancer Society (grant number 10014); and all participating pharmaceutical companies (grant numbers not applicable): Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Novartis, Merck Sharp & Dohme, Pfizer and Roche.

PY - 2019/5

Y1 - 2019/5

UR - https://www.scopus.com/pages/publications/85067377129

U2 - 10.1093/annonc/mdz119

DO - 10.1093/annonc/mdz119

M3 - Editorial

C2 - 31038154

AN - SCOPUS:85067377129

SN - 0923-7534

VL - 30

SP - 663

EP - 665

JO - Annals of Oncology

JF - Annals of Oncology

IS - 5

M1 - mdz119

ER -